In vitro glutamate-stimulated release of dopamine from nucleus accumbens core and shell of spontaneously hypertensive rats.
Spontaneously hypertensive rats (SHR) are used as a model for attention-deficit hyperactivity disorder (ADHD) since SHR display the major symptoms of ADHD (hyperactivity, impulsivity, inablity to sustain attention during behavioral tasks). We previously showed that electrical and/or K+-stimulated release of dopamine (DA) from nerve terminals in the prefrontal cortex, nucleus accumbens, and caudate-putamen of SHR was significantly lower than that of Wistar-Kyoto (WKY) control rats. The aim of the present investigation was to determine whether glutamate-stimulated release of DA from nucleus accumbens core and shell of SHR was significantly different from that of WKY. Using an in vitro superfusion technique, we showed that glutamate-stimulated release of [3H]DA from striatal slices is mediated by glutamate activation of AMPA receptors and that glutamate-stimulated release of [3H]DA from nucleus accumbens core and shell of 4-6-week-old SHR and WKY is not significantly different. Glutamate-stimulated release of [3H]DA from SHR shell is significantly lower than SHR core and there is also a tendency for glutamate-stimulated [3H]DA release from SHR shell to be lower than release from WKY shell.
Russell
Vivienne Ann
VA
Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa. russell@curie.uct.ac.za
D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology*; D006973:Hypertension / Q000235:genetics / Q000378:metabolism*; D066298:In Vitro Techniques; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism*; D010477:Perfusion; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D018091:Receptors, AMPA / Q000819:agonists
D018691:Excitatory Amino Acid Antagonists; D011810:Quinoxalines; D018091:Receptors, AMPA; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D018698:Glutamic Acid; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D004298:Dopamine